Literature DB >> 304012

Serum half-life and organ distribution of radiolabeled colony stimulating factor in mice.

A W Burgess, D Metcalf.   

Abstract

Granulocyte-macrophage colony stimulating factor (GM-CSF) from mouse lung conditioned medium has recently been purified. This GM-CSF was radioiodinated using the chloramine T method, but dimethylsulfoxide was needed to prevent the loss of biological activity during the iodination. 125I-labeled GM-CSF was isolated from the reaction mixture by gel filtration and affinity chromatography with concanavalin A-Sepharose. One hour after intravenous injection of 125I-labeled GM-CSF almost 80% of the radioactivity was still localized in the serum. 125I-labeled GM-CSF was cleared from the blood of C57BL mice with a serum half-life of 7.3 +/- 1.3 hours. Six hours after intravenous injection 125I-GM-CSF appeared to be distributed throughout most of the tissues of C57BL mice. There was no selective concentration of 125I-labeled GM-CSF in the bone marrow, but levels in the kidney were three times higher than expected from the distribution of 125I-labeled mouse serum albumin. 125I detected in the blood 6 hours after injection of 125I-labeled GM-CSF was precipitable with trichloroacetic acid and bound to concanavalin A-Sepharose. 125I detected in the urine was not macromolecular and appeared to result from the degradation of 125I-labeled GM-CSF.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 304012

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  A case of gallbladder cancer producing granulocyte-colony-stimulating factor.

Authors:  T Takeda; A Ichiyanagi; K Sano; J Yoshida; Y Tsutsumi; T Miyaji
Journal:  Gastroenterol Jpn       Date:  1990-12

2.  Granulocyte/macrophage colony-stimulating factor from mouse lung conditioned medium. Purification of multiple forms and radioiodination.

Authors:  A W Burgess; D Metcalf; L G Sparrow; R J Simpson; E C Nice
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

3.  Synovial Cytokines and the MSIS Criteria Are Not Useful for Determining Infection Resolution After Periprosthetic Joint Infection Explantation.

Authors:  Salvatore J Frangiamore; Marcelo B P Siqueira; Anas Saleh; Thomas Daly; Carlos A Higuera; Wael K Barsoum
Journal:  Clin Orthop Relat Res       Date:  2016-07       Impact factor: 4.176

Review 4.  The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Authors:  Xiaohu Zheng; Yaqi Wu; Jiacheng Bi; Yingying Huang; Ying Cheng; Yangyang Li; Yuwei Wu; Guoshuai Cao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 11.530

5.  Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology.

Authors:  Aurelien Lathuiliere; Remi Vernet; Emily Charrier; Muriel Urwyler; Olivier Von Rohr; Marie-Claude Belkouch; Valentin Saingier; Thomas Bouvarel; Davy Guillarme; Adrien Engel; Patrick Salmon; Thomas Laumonier; Julien Grogg; Nicolas Mach
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-01       Impact factor: 5.849

6.  Specific binding of radioiodinated granulocyte-macrophage colony-stimulating factor to hemopoietic cells.

Authors:  F Walker; A W Burgess
Journal:  EMBO J       Date:  1985-04       Impact factor: 11.598

7.  Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis.

Authors:  Yu-Min Chuang; Liangmei He; Michael L Pinn; Ya-Chea Tsai; Max A Cheng; Emily Farmer; Petros C Karakousis; Chien-Fu Hung
Journal:  Cell Mol Immunol       Date:  2020-05-07       Impact factor: 11.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.